TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL

被引：3
|
作者：
Griffiths, C. E. [1 ]
Papp, K. A. [2 ]
Kimball, A. B. [3 ]
Randazzo, B. [4 ]
Wasfi, Y. [4 ]
Li, S. [4 ]
Shen, Y. -K. [4 ]
Blauvelt, A. [5 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[3] Beth Israel Deaconess Med Ctr Inc, Harvard Med Fac Phys, Boston, MA USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Oregon Med Res Ctr, Portland, OR USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5825
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0912
引用
收藏
页码：1580 / 1581
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of systemic treatments for moderate-to-severe psoriasis
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02)
  • [32] Efficacy and safety of picankibart in moderate-to-severe plaque psoriasis: a randomized, double-blind, Phase 3 CLEAR-1 trial
    Shi, Yuling
    Qin, Lanying
    Li, Yumei
    Cui, Yong
    Zhang, Shifa
    Chen, Mingxia
    Cai, Chenghang
    Qian, Lei
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [33] Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Song, Michael
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Han, Chenglong
    Blauvelt, Andrew
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 848 - 856
  • [34] Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study
    Zhao, Zheng
    Mu, Zhanglei
    Zhao, Yan
    Zhang, Jianzhong
    Cai, Lin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [35] Guselkumab vs. secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal
    Wan, M. T.
    Takeshita, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (02) : 259 - 260
  • [36] Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan
    Tanghetti, Emil A.
    Bagel, Jerry
    Yamauchi, Paul S.
    Gold, Linda Stein
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 855 - 861
  • [37] Safety of guselkumab in patients with moderate-to-severe psoriasis: Pooled analyses across clinical studies
    Lebwohl, Mark
    Rowland, Katelyn
    Miller, Megan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [38] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [39] Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials
    Lebwohl, Mark
    Papp, Kim A.
    Tyring, Stephen
    Krueger, James
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB180 - AB180
  • [40] Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial
    Landells, Ian
    Marano, Collen
    Hsu, Ming-Chun
    Li, Shu
    Eichenfield, Lawrence
    Hoeger, Peter
    Menter, Alan
    Paller, Amy
    Taieb, Alain
    Randazzo, Bruce
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB202 - AB202
12345